10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus - Full Text View

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus (PEER)

This study is currently recruiting participants.

Verified September 2011 by Valeant Pharmaceuticals International, Inc.

First Received on December 5, 2007. Last Updated on September 2, 2011 History of Changes

Sponsor:	Valeant Pharmaceuticals International, Inc.
Collaborator:	Clinical Research Computing Unit (University of Pennsylvania)
Information provided by (Responsible Party):	Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier:	NCT00568997

Purpose

This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

Condition	Intervention
Atopic Dermatitis	Drug: Pimecrolimus

Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)

Resource links provided by NLM:

MedlinePlus related topics: Cancer Eczema

Drug Information available for: Pimecrolimus

U.S. FDA Resources

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:

The incidence rate of systemic malignancies in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream [ Time Frame: 10 years of observation with 6-month reporting intervals ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

The incidence rate of lymphoma in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream [ Time Frame: 10 years of observation with 6-month reporting intervals ] [ Designated as safety issue: Yes ]
The incidence rate of thyroid cancer in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream [ Time Frame: 10 years of observation with 6-month reporting intervals ] [ Designated as safety issue: Yes ]
The incidence rate of cutaneous malignancy in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream [ Time Frame: 10 years of observation with 6-month reporting intervals ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	8000
Study Start Date:	June 2004
Estimated Study Completion Date:	December 2021

Groups/Cohorts	Assigned Interventions
1 Single-group	Drug: Pimecrolimus Pimecrolimus 1% cream Other Name: Elidel

Eligibility

Ages Eligible for Study:	2 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Children (ages 2-17 years)

Criteria

Inclusion Criteria:

males and females
greater than or equal to 2 years and less than or equal to 17 years at enrollment
diagnosis of atopic dermatitis (confirmed by treating physician)
applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks

Exclusion Criteria:

past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease
past or present use of oral immunosuppressive therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568997

Contacts

Contact: Valeant Pharmaceuticals

908-927-1400

Locations

United States, Pennsylvania
Registry	Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: NA NA
Contact: NA

Sponsors and Collaborators

Valeant Pharmaceuticals International, Inc.

Clinical Research Computing Unit (University of Pennsylvania)

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier:	NCT00568997 History of Changes
Other Study ID Numbers:	CASM981C2311
Study First Received:	December 5, 2007
Last Updated:	September 2, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Valeant Pharmaceuticals International, Inc.:

Atopic dermatitis, eczema, children, pediatric patients, pimecrolimus, malignancy, registry

Additional relevant MeSH terms:

Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pimecrolimus
Tacrolimus
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic

Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 12, 2012